NKTR
The analyst note says: not so fast, bears
Jefferies came back with a fresh Buy rating on Nektar Therapeutics and held its $121 price target after the company posted positive Phase 2 data for its alopecia areata drug, rezpegaldesleukin. In plain English: the bank looked at the latest readout and basically said, “Yep, still like it.”
Why this matters
The update wasn’t just a polite thumbs-up. Nektar said about 28% of patients hit SALT scores below 20 at the 52-week mark, which topped Jefferies’ expectation of 20% to 25%. That matters because in biotech land, beating expectations is the difference between “promising” and “please keep the runway lights on.”
The science keeps stretching the story
The company also said the safety profile looked consistent with earlier data, which is the kind of boring-but-important detail investors love. No surprise monster side effects, no ugly new twist — just more evidence that the therapy may have staying power.
Nektar is also lining up an end-of-Phase 2 meeting in the second quarter and plans to drop 24-week off-treatment data in the fourth quarter. Translation: this story isn’t over. If you own the stock, you’ve got more catalysts on the calendar than a holiday-decorated fridge.
Big picture
This is one of those biotech moments where the stock can keep trading on hope, but only if the data keeps acting like a reliable sequel. Jefferies thinks the script still works — and for a name that’s already ripped 789% over the past year, that’s not nothing.